Global Attention Deficit Hyperactivity Disorder (ADHD) Market - 2023-2030

Global Attention Deficit Hyperactivity Disorder (ADHD) Market - 2023-2030

The Global Attention Deficit Hyperactivity Disorder (ADHD) Market reached US$ 15.7 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 21.9 billion by 2030. The Global Attention Deficit Hyperactivity Disorder Market is expected to exhibit a CAGR 4.3% during the forecast period 2023-2030.

Recent market trends include the shift towards non-stimulant medications, the expansion of digital health solutions, and a growing focus on combination therapies. The Global Attention Deficit Hyperactivity Disorder Market has expanded continuously in recent years. It is a neurological condition that affects both children and adults. ADHD is defined by persistent inattention, hyperactivity, and impulsivity, which can impair everyday functioning and quality of life.

The global attention deficit hyperactivity disorder market scope comprises components encompassing drug types such as stimulant drugs and non-stimulant drugs, which has increased usage of attention deficit hyperactivity disorder market share. The global market for attention deficit hyperactivity disorder is expanding as a result of factors including the increasing prevalence of ADHD, growing public awareness, and growing emphasis on R&D.

Market Dynamics

An Increase in Demand for Effective Treatments Drive the Growth of the Attention Deficit Hyperactivity Disorder Market

The global ADHD market is driven by rising demand for effective treatments and drugs. Stimulant medicines have long been the treatment of choice for ADHD, and their dominance in the pharmaceutical market attests to their effectiveness. These drugs, such as methylphenidate, amphetamine salts, and dextroamphetamine, boost the levels of particular neurotransmitters in the brain, resulting in improved focus and less impulsivity.

Furthermore, the increasing popularity of non-stimulant drugs such as Strattera emphasizes the need for new treatment choices that provide efficacy while minimizing negative effects. Because of their favorable safety profile, non stimulant medicines have gained recognition among patients and healthcare professionals. For instance, in March 2022, Xelstrym (dextroamphetamine) received the first FDA-approved amphetamine patch to treat ADHD in adults and kids above six. Thereby driving the market over the forecast period.

Growing Awareness is the Major Driver in the Global Attention Deficit Hyperactivity Disorder Market

Growing ADHD awareness among healthcare professionals and the general public is a major driver of market expansion in the ADHD sector. There has been a greater awareness of the illness, resulting in earlier identification and treatments. The US Department of Health and Human Services and the European ADHD Alliance are two organizations that promote better treatment options and work to improve the quality of life for people with ADHD.

The CDC collaborates with states and partner organizations to raise awareness and identify best practices supporting ADHD behavior therapy. Experts advise treating ADHD in children under the age of six with behavior therapy before using medication. Thus, increasing awareness about the disorder will drive the market over the forecast period.

The Limited Availability of Non-Stimulant ADHD drugs will Hamper the Growth of the Market.

The scarcity of non-stimulant ADHD medications hampers the ADHD market. While stimulant drugs dominate the market, demand for non-stimulant options such as atomoxetine (Strattera) is increasing. However, the limited availability of these non-stimulant medicines makes satisfying the different treatment needs of people with ADHD difficult. This constraint stifles market growth by limiting treatment alternatives and perhaps underserving a section of the ADHD patient population.

COVID-19 Impact Analysis

The financial health of companies across all industries has been impacted by the COVID-19 pandemic and lockdown in numerous nations worldwide. Therefore, for the period of the COVID-19 public health emergency, the U.S. Food and Drug Administration (FDA) issued guidelines that include general considerations to aid sponsors and researchers, ensuring the safety of trial participants, adhering to good clinical practice (GCP), and minimizing risks to trial integrity.

Russia-Ukraine War Impact Analysis

The conflict between Russia and Ukraine can potentially have an array of effects on the global market for ADHD. There are several essential things to consider, including disruptions in the supply chains for ADHD medications, the state of the economy, problems with the healthcare system, and the psychological effects on people.

These elements may result in possible shortages, varying demands, restricted access to healthcare services, and a rise in the prevalence of ADHD. It will be essential to monitor the situation and take the necessary steps to prevent disruptions and guarantee that ADHD medicines remain accessible.

Segment Analysis

The Global Attention Deficit Hyperactivity Disorder Market is segmented based on drug type, age group, distribution channel, and region.

Retail Pharmacies Distribution Channel Segment Accounts for 61.2% of Market Share Owing to Ease of Access

The retail pharmacy segment dominates the ADHD industry since it is the primary point of purchase for patients seeking ADHD drugs and therapies. This dominance can be explained by the prevalence of outpatient treatment for ADHD patients.

Furthermore, there has been an increased emphasis on patient care efforts such as Greenway Medical Technologies, which provides consumers with personal Electronic Health Records (EHRs). These EHRs assist patients in keeping track of their drug history and receiving basic treatment, which contributes to the importance of retail pharmacies in the ADHD industry.

Geographical Analysis

North America Accounted for Approximately 62.4% of the Market Share Owing to the Increasing Prevalence of ADHD.

North America dominates the Global ADHD Market because of factors such as a higher prevalence of ADHD, greater awareness, early diagnosis, and well-established healthcare infrastructure. The region has a huge patient pool and favorable reimbursement regulations encourage the market's growth. Along with the U.S., Canada is also a country that has a higher prevalence of ADHD.

According to the Centre for ADHD Awareness, Canada (CADDAC), ADHD, a prevalent neurodevelopmental disorder in Canada, affects many of the population. ADHD affects around 4-6% of adults and 5-7% of children in Canada, totaling approximately 1.8 million Canadians. This indicates that about 1 in every 21 Canadians has been diagnosed with the disorder. Therefore, owing to the growing prevalence of ADHD in North America to dominate the market over the forecast period.

Competitive Landscape

The major global players in the attention deficit hyperactivity disorder market include Supernus Pharmaceuticals, Inc., Pfizer Inc, Novartis AG, Eli Lilly and Company, GlaxoSmithKline PLC, Mallinckrodt Pharmaceuticals, Johnson & Johnson, Hisamitsu Pharmaceutical Co., Inc., Chongqing Fujin Biology Medical Company, Purdue Pharma LP, and among others.

Why Purchase the Report?
• To visualize the Global Attention Deficit Hyperactivity Disorder Market segmentation based on drug type, age group, distribution channel, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous attention deficit hyperactivity disorder market-level data points with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available as Excel, consisting of key products of all the major players.

The Global Attention Deficit Hyperactivity Disorder Market Report Would Provide Approximately 53 Tables, 54 Figures And 195 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies